BRIEF published on 07/28/2026 at 15:25, 1 month 14 days ago Edison Research analyse les solides performances de BB Biotech au deuxième trimestre Stratégie D'investissement Perspectives Du Marché Expansion Du Portefeuille BB Biotech Résultats Du Deuxième Trimestre 2026
BRIEF published on 07/28/2026 at 15:25, 1 month 14 days ago Edison Research Analyzes BB Biotech's Robust Q2 Performance Investment Strategy Portfolio Expansion Market Outlook BB Biotech Q2 2026 Results
PRESS RELEASE published on 07/28/2026 at 15:20, 1 month 14 days ago Edison issues report on BB Biotech (BION) Edison issues favorable report on BB Biotech (BION) Q226 results, highlighting NAV growth, portfolio adjustments, and revised payout policy, supporting positive outlook for biotechnology investing Biotechnology Edison Report BB Biotech Q226 Results
BRIEF published on 07/24/2026 at 07:05, 1 month 19 days ago BB Biotech AG Reports Interim Gains and Adjusts Dividend Policy Dividend Policy Investment Portfolio Interim Report BB Biotech Net Gain
BRIEF published on 07/24/2026 at 07:05, 1 month 19 days ago BB Biotech AG annonce des résultats intermédiaires et ajuste sa politique de dividendes. Politique De Dividendes Portefeuille D'investissement BB Biotech Rapport Intérimaire Gain Net
BRIEF published on 07/24/2026 at 07:05, 1 month 19 days ago BB Biotech Q2 2026: Robust NAV Performance Amid Strategic Investments Portfolio Diversification Dividend Policy Strategic Investments M&A Activity Biotechnology Performance
BRIEF published on 07/24/2026 at 07:05, 1 month 19 days ago BB Biotech T2 2026 : Forte performance de l’actif net grâce à des investissements stratégiques Investissements Stratégiques Politique De Dividendes Diversification Du Portefeuille Activité De Fusions Et Acquisitions Performance En Biotechnologie
PRESS RELEASE published on 07/24/2026 at 07:00, 1 month 19 days ago EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy BB Biotech AG publishes its interim report for the first half of 2026, reporting a net gain and revising its dividend policy. Details at www.bbbiotech.ch Financial Results Investment Company Dividend Policy BB Biotech AG Interim Report
PRESS RELEASE published on 07/24/2026 at 07:00, 1 month 19 days ago BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning BB Biotech AG reports strong NAV outperformance in Q2 2026, driven by disciplined stock selection and portfolio positioning, new investments, and revised dividend policy Dividend Policy BB Biotech AG Stock Selection Q2 2026 NAV Outperformance
BRIEF published on 04/24/2026 at 07:05, 4 months 18 days ago BB Biotech AG Reports Q1 2026 Interim Results Drug Development Net Loss Investment Portfolio BB Biotech Q1 2026
Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
